Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 7, 2019

Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis

Galapagos has commenced the NOVESA Phase IIa trial to assess the efficacy, safety and pharmacokinetic / pharmacodynamic (PK/PD) of GLPG1690 for the treatment of patients with systemic sclerosis (SSc) or scleroderma.

Galapagos has commenced the NOVESA Phase IIa trial to assess the efficacy, safety and pharmacokinetic / pharmacodynamic (PK/PD) of GLPG1690 for the treatment of patients with systemic sclerosis (SSc) or scleroderma.

The double-blind and placebo-controlled trial is expected to enrol 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis and has no approved drugs for its treatment.

Patients with diffuse cutaneous SSc are at a higher risk of developing fibrosis of several internal organs, including the lungs.

The primary objective of the NOVESA trial is the improved Rodnan skin score (mRSS) at 24 weeks.

“Thanks to the broad MoA of ‘1690, this compound has the potential to address the important unmet medical need in SSc.”

mRRS is designed to assess the skin thickness as a surrogate measure of disease severity and mortality.

The trial’s secondary objectives and exploratory goals comprise forced vital capacity (FVC), high-resolution computed tomography (HRCT), quality of life as assessed by quality of life questionnaire (QoL-Q), and combined response index for systemic sclerosis (CRISS).

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Galapagos chief medical officer Dr Walid Abi-Saab said: “In addition to our Phase III programme in IPF, we are excited to broaden our development program with ‘1690 to a second indication.

“Moreover, SSc is particularly interesting, as this disease straddles our expertise in autoimmune diseases as well as in fibrosis.

“Thanks to the broad MoA of ‘1690, which is both anti-inflammatory and anti-fibrotic, this compound has the potential to address the important unmet medical need in SSc.”

SSc is currently estimated to affect nearly 90,000 patients in the US and Europe.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU